UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Unique features of trabectedin mechanism of action

Cancer chemotherapy and pharmacology, 2016-04, Vol.77 (4), p.663-671

2016

Volltextzugriff (PDF)

A review of trabectedin (ET-743): a unique mechanism of action

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2157-2163

2010

Volltextzugriff (PDF)

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Cancer cell, 2013-02, Vol.23 (2), p.249-262

2013

Volltextzugriff (PDF)

Cancer chemotherapy: A critical analysis of its 60 years of history

Critical reviews in oncology/hematology, 2012-11, Vol.84 (2), p.181-199

2012

Volltextzugriff (PDF)

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin

Scientific reports, 2016-10, Vol.6 (1), p.35100-35100, Article 35100

2016

Volltextzugriff (PDF)

Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment

Marine Drugs, 2014-01, Vol.12 (2), p.719-733

2014

Volltextzugriff (PDF)

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells

BMC cancer, 2018-02, Vol.18 (1), p.164-164, Article 164

2018

Volltextzugriff (PDF)

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations

Nucleic acids research, 2011-10, Vol.39 (18), p.8248-8257

2011

Volltextzugriff (PDF)

Unique features of trabectedin mechanism of action

Cancer Chemotherapy and Pharmacology, 2016-04, Vol.77 (4), p.663-671

2016

Volltextzugriff (PDF)

Deep Neural Frameworks Improve the Accuracy of General Practitioners in the Classification of Pigmented Skin Lesions

Diagnostics (Basel), 2020-11, Vol.10 (11), p.969

2020

Volltextzugriff (PDF)

Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death

PloS one, 2015-10, Vol.10 (10), p.e0140782-e0140782

2015

Volltextzugriff (PDF)

Drug Resistance and the Solid Tumor Microenvironment

JNCI : Journal of the National Cancer Institute, 2007-10, Vol.99 (19), p.1441-1454

2007

Volltextzugriff (PDF)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

British journal of cancer, 2017-08, Vol.117 (5), p.628-638

2017

Volltextzugriff (PDF)

Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

Clinical cancer research, 2008-07, Vol.14 (14), p.4511-4516

2008

Volltextzugriff (PDF)

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines

Journal of breast cancer, 2015-12, Vol.18 (4), p.329

2015

Volltextzugriff (PDF)

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells

PloS one, 2011-04, Vol.6 (4), p.e19042-e19042

2011

Volltextzugriff (PDF)

Why we do what we do. A brief analysis of cancer therapies

EXCLI journal, 2020-01, Vol.19, p.1401-1413

Galmarini, Carlos M

2020

Volltextzugriff (PDF)

ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment

European journal of pharmacology, 2011-09, Vol.667 (1), p.91-99

2011

Volltextzugriff (PDF)

Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts

Marine drugs, 2013-12, Vol.11 (12), p.4858-4875

2013

Volltextzugriff (PDF)

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells

Molecular cancer therapeutics, 2005-08, Vol.4 (8), p.1268-1276

2005

Volltextzugriff (PDF)

Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival

British journal of cancer, 2018-11, Vol.119 (11), p.1410-1420

2018

Volltextzugriff (PDF)

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

Future oncology (London, England), 2019-01, Vol.15 (3), p.231-239

2019

Volltextzugriff (PDF)

Lessons from Hippocrates: Time to Change the Cancer Paradigm

International Journal of Chronic Diseases, 2020-06, Vol.2020 (2020), p.1-14

2020

Volltextzugriff (PDF)

Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines

Molecular cancer therapeutics, 2008-10, Vol.7 (10), p.3373-3380

2008

Volltextzugriff (PDF)

The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability

Molecular cancer research, 2019-03, Vol.17 (3), p.773-782

2019

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(121)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(135)
Buchkapitel
(1)

Sprache

Englisch
(135)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(83)
Humans
(82)
Oncology
(43)
Animals
(41)
Female
(27)
Pharmacology & Pharmacy
(26)
Biological And Medical Sciences
(24)
Cell Line, Tumor
(24)
Medical Sciences
(24)
Antineoplastic Agents - Pharmacology
(21)
Drug Resistance
(21)
Pharmacology. Drug Treatments
(19)
Hematology
(18)
Neoplasms - Drug Therapy
(18)
Antineoplastic Agents
(17)
Male
(16)
Mice
(16)
Apoptosis
(15)
Drug Resistance, Neoplasm
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Unique features of trabectedin mechanism of action

A review of trabectedin (ET-743): a unique mechanism of action

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

Cancer chemotherapy: A critical analysis of its 60 years of history

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin

Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment

Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells

Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations

Unique features of trabectedin mechanism of action

Deep Neural Frameworks Improve the Accuracy of General Practitioners in the Classification of Pigmented Skin Lesions

Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death

Drug Resistance and the Solid Tumor Microenvironment

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models

Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines

Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells

Why we do what we do. A brief analysis of cancer therapies

ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment

Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells

Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line

Lessons from Hippocrates: Time to Change the Cancer Paradigm

Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines

The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability

Suchergebnisse filtern